What question did this study set out to answer?

August 2, 2026CellsOpen Access

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

View Full Paper

Ask AI

Bookmark

Authors

EBEduardo BravoUniversity of Miami CPClaudia Cabrera PastranaUniversity of Miami ELErica LamkinUniversity of Miami

Discussion

Member takes

Implication

Review highlights therapeutic strategies targeting Bruton's tyrosine kinase in chronic lymphocytic leukemia, indicating the need for selectivity and overcoming resistance.

Key Points

This review aims to summarize the therapeutic strategies targeting Bruton's tyrosine kinase in chronic lymphocytic leukemia, focusing on selectivity and resistance mechanisms.
Reviewed design of irreversible and reversible inhibitors targeting BTK.
Discussed Proteolysis-targeting chimera (PROTAC) degraders for BTK.
Included analysis of crystal structures of compounds bound to BTK.
Identified resistance mutations highlight the need for alternative BTK-targeting strategies.
Developed selective inhibitors and degraders show promise in overcoming BTK resistance.

Cite This Study

Bravo et al. (2026) studied this question.

synapsesocial.com/papers/6a6eeacb1b0468a7eeab34d0 https://doi.org/10.3390/cells15151383

View Full Paper

Ask AI

Bookmark

Implication

Review highlights therapeutic strategies targeting Bruton's tyrosine kinase in chronic lymphocytic leukemia, indicating the need for selectivity and overcoming resistance.

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider